Realgar transforming solution is involved of JNK, P38 MAPK pathway in down-regulating Ras/MAPK pathway in Caenorhabditis elegans

被引:0
|
作者
LIU Dong-ling [1 ,2 ]
ZHI De-juan [1 ]
WAN Feng-qi [1 ]
WANG Meng-qi [1 ]
ZHOU Ting [1 ,2 ]
BAI Yan-li [1 ,2 ]
LI Hong-yu [1 ]
机构
[1] Institute of Microbiology,School of Life Sciences,Lanzhou University
[2] Gansu University of Chinese Medicine
关键词
realgar transforming solution; C; elegans; P38; JNK/MAPK pathway;
D O I
暂无
中图分类号
R285.5 [中药实验药理];
学科分类号
摘要
OBJECTIVE To investigate the effect and the mechanisms of realgar transforming solution(RTS) on down-regulating over activated ras. METHODS we used the optimizing technical processes to obtain the RTS, and evaluate the mechanisms of RTS on down-regulating overactivated ras in Caenorhabditis elegans. RESULTS We found that the mRNA level of let60 and lin45 significantly decreased following exposure to RTS, but mRNA levels of mpk1 were not statistically significant in let60/ras(gf) mutant. RTS together with sorafenib(RAF inhibitors) significantly enhanced the activity of RTS on down-regulating overactivated ras more than RTS only, but 50 μmol·L;PD98059, a specific ERK inhibitor did not. Lin45 gene RNAi decreased the ability of RTS on down-regulating overactivated ras significantly, but mpk1 gene RNAi did not, indicating that the activity of RTS on down-regulating overactivated ras mainly through targeting to lin45/raf. In addition, RTS significantly increased mR NA level of pmk1/p38 and jnk1/jnk in let-60/ras(gf) mutant, 50 μmol·L;SB203580(p38 inhibitor) and SP600125(JNK inhibitor) significantly attenuated the effects of RTS on down-regulating overactivated ras in some degree, and pmk1, jnk1 gene RNAi displayed the similar results, suggesting that P38 and JNK/MAPK pathways in some degree were involved in the effects of RTS on down-regulating overactivated ras in C. elegans. CONCLUSION Realgar transforming solution down-regulate the Ras/MAPK pathway through JNK and P38 MAPK pathways.
引用
收藏
页码:690 / 691
页数:2
相关论文
共 50 条
  • [21] Caenorhabditis elegans mom-4 is required for the activation of the p38 MAPK signaling pathway in the response to Pseudomonas aeruginosa infection
    Ajing Xu
    Guojun Shi
    Feng Liu
    Baoxue Ge
    Protein & Cell, 2013, 4 (01) : 53 - 64
  • [22] P38 MAPK signaling pathway is involved in butyrate induced VDR-expression
    Daniel, C
    Gaschott, T
    Schroeder, O
    Stein, J
    GASTROENTEROLOGY, 2004, 126 (04) : A395 - A395
  • [23] Caenorhabditis elegans mom-4 is required for the activation of the p38 MAPK signaling pathway in the response to Pseudomonas aeruginosa infection
    Xu, Ajing
    Shi, Guojun
    Liu, Feng
    Ge, Baoxue
    PROTEIN & CELL, 2013, 4 (01) : 53 - 61
  • [25] Prions activate a p38 MAPK synaptotoxic signaling pathway
    Fang, Cheng
    Wu, Bei
    Le, Nhat T. T.
    Imberdis, Thibaut
    Mercer, Robert C. C.
    Harris, David A.
    PLOS PATHOGENS, 2018, 14 (09)
  • [26] Syntenin regulates melanogenesis via the p38 MAPK pathway
    Sun, Lijun
    Guo, Chunyan
    Yan, Liting
    Li, Huijin
    Sun, Jingying
    Huo, Xueping
    Xie, Xin
    Hu, Jun
    MOLECULAR MEDICINE REPORTS, 2020, 22 (02) : 733 - 738
  • [27] PFKFB3 regulation by p38 MAPK pathway
    Novellasdemunt Vilaseca, L.
    Cuesta, A. M.
    Ventura, F.
    Rosa, J. L.
    Rider, M. H.
    Sabate, A. N.
    Bach, R. B.
    FEBS JOURNAL, 2012, 279 : 271 - 271
  • [28] The p38 MAPK stress pathway as a tumor suppressor or more?
    Loesch, Mathew
    Chen, Guan
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2008, 13 : 3581 - 3593
  • [29] Emodin inhibits formation of hypertrophic scars through regulating the p38/MAPK signaling pathway
    He, Bin
    Chen, Jia
    Liu, Liang
    Wang, Hao
    Wang, Shaohua
    Li, Ping
    Zhou, Jianda
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2018, 11 (11): : 12310 - 12317
  • [30] Shionone Relieves Ulcerative Colitis by Regulating the p38 MAPK/NF-κB Pathway
    Wei, Ping
    Wang, Yuyao
    Li, Xuejing
    Che, Zhaoping
    REVISTA BRASILEIRA DE FARMACOGNOSIA-BRAZILIAN JOURNAL OF PHARMACOGNOSY, 2024, 34 (05): : 1071 - 1078